GenMark Diagnostics (GNMK) Misses Q3 EPS by 2c

GenMark Diagnostics (NASDAQ: GNMK) reported Q3 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $14.56 million.

For full year 2017, GenMark expects revenue to range from $51 - $53 million and gross margin to range from 38% to 40%. The Company expects to exit 2017 with 185-200 ePlex placements.

For earnings history and earnings-related data on GenMark Diagnostics (GNMK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c